OBJ Executes Collaboration Agreement With Multi-National Partner For BodyGuard

PERTH, WA: OBJ Limited (ASX: OBJ) has executed a Collaboration Agreement with an international manufacturing and distribution partner, initially focused on the commercial development of OBJ’s BodyGuard technology. The partner is a well-renowned manufacturer and distributor of industrial adhesive tapes for the electronics, automotive, health care, medical devices, packaging and construction industries.

In addition to the commercial development of BodyGuard, the agreement will contain provisions for various outcomes from the collaboration including granting the partner first right of refusal to manufacture the BodyGuard product range. The partner will also have the non-exclusive right to distribute the BodyGuard product range in certain markets once it is fully commercialised.

OBJ will contribute its knowledge and expertise in formulation and claims support development, while the partner will contribute manufacturing, production engineering, distribution and packaging expertise.

The partnering corporation is one of the largest adhesive companies in the world, with sales in excess of US$7 billion and more than 100 manufacturing centres globally. It produces transdermal drug patches, medical devices, medical materials, taping products, kinesiology and sports tapes.

“It is the partner’s vast experience in the manufacture of the world’s leading kinesiology tape products that first attracted us to this potential working relationship,” said Glyn Denison, OBJ’s Non-Executive Chairman.

“Establishing a high-volume, low-cost manufacturing capability is a major objective for BodyGuard as it allows for the development of various formulations required by distributors. The establishment of this collaboration agreement with such a reputable company is a major step forward in the last stage of BodyGuard’s development program, that being a commercial end product that can be economically manufactured. The potential to encompass distribution in the same agreement is an excellent outcome for OBJ.”

The collaboration agreement will also lead to OBJ introducing its micro-array technology for possible integration within the partner’s existing product range.

OBJ’s partners and customers will benefit from the best and most cost-effective production technologies, while the partner can explore the value-added potential of OBJ’s technologies across its broad product range.

The collaboration will cover all aspects of mass production of the BodyGuard range in an appropriate high-quality, low-cost environment. It will also cover various studies designed to optimise the alternative formulations and consumer responses.

The partnering company will draw support for the project from its various global manufacturing centres to ensure the manufacturability of BodyGuard.

For further information contact:

Matthew Wright - Investor Relations
P: +61 (0) 451 896 420
matt@nwrcommunications.com.au

About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

Back to news